الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 62 |  |  |
| | | from | 62 | | |
Abstract
Ovarian hyperstimulation syndrome is the most serious iatrogenic complication of ovarian stimulation, usually self-limited, but occasionally life threatening. Although the pathophysiology of this syndrome has not been completely elucidated, the underlying mechanism responsible for the clinical manifestations of OHSS appears to be an increase in capillary permeability of mesothelial surfaces. Many preventive strategies have been tried but there is as yet no means of completely preventing it.
The aim of the present study was to prevent ovarian hyperstimulation syndrome (OHSS) in high risk patients undergoing intra-cytoplasmic sperm injection (ICSI) cycles by using quinagolide and cabergoline.
This study was conducted on 100 infertile female patients high risk for developing OHSS undergoing intra-cytoplasmic sperm injection (ICSI) cycle.
The cases were then be divided into2 groups
group I: 50 patients were given Quinagolide 75 micrograms daily from the day of HCG administration for 8 days.
group II: 50 patients were given Cabergoline 0.5 mg daily from the day of HCG administration for 8 days.
All patients accepted and consented to the IVF/ICSI program group
Our results revealed that:
- There were no statistical significant differences between the two studied groups regarding BMI, patients’ age, infertility duration, type and cause of infertility.
- Estradiol levels on day of HCG showed no statistical significant difference between the 2 groups with a mean of 4343.5 ± 628.53 and 4390.6 ± 724.9 for Quinagolide and cabergoline groups respectively.
- Among the two studied groups there was no statistical significant difference between the mean of the number of oocytes retrieved and injected, also there was no statistical significance as regards total number of embryos or embryos transferred between the two groups.